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Abstract
Rationale Experimental research has shown that 3,4-methyl-
enedioxymethamphetamine (MDMA) can improve some
psychomotor driving skills when administered during the
day. In real life, however, MDMA is taken during the night,
and driving may likely occur early in the morning after a night
of “raving” and sleep loss.
Objectives The present study assessed the effects of
MDMA on road-tracking and car-following performance
in on-the-road driving tests in normal traffic.
Methods Sixteen recreational MDMA users participated in
a randomized double-blind placebo-controlled four-way
cross-over design. They received single, evening doses of
0, 25, 50, and 100 mg MDMA on separate occasions.
Actual driving tests were conducted in the evening when
MDMA serum concentrations were maximal and in the
morning after a night of sleep loss.
Results The primary measure of driving, i.e., standard
deviation of lateral position (SDLP, a measure of weaving)
was significantly increased during driving tests in the
morning in all treatment conditions, irrespective of MDMA
dose and concentration. The increments in SDLP were of
high clinical relevance and comparable to those observed
for alcohol at blood alcohol concentrations >0.8 mg/mL.
These impairments were primarily caused by sleep loss.
Conclusions In general, MDMA did not affect driving
performance nor did it change the impairing effects of sleep
loss. It is concluded that MDMA cannot compensate for the
impairing effects of sleep loss and that drivers who are
under the influence of MDMA and sleep deprived are unfit
to drive.
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Introduction
3,4-Methylenedioxymethamphetamine (MDMA) is the
main psychoactive constituent of ecstasy. Ecstasy has
stimulant and hallucinogenic effects and has often been
described as an entactogenic drug because of its character-
istic that it makes people feel close to each other. Ecstasy is
a popular drug: in 2007 9.5 million European adults had
ever used ecstasy, which is 2.8% of the general population
(EMCDDA 2008). In the USA a trend of increasing ecstasy
use among adults in 2006–2007 is noticeable, which
remained stable in 2008 (SAMHSA 2009). In Europe as
well as in the USA, ecstasy is one of the most commonly
used illicit drugs after cannabis.
The widespread use of ecstasy might have implications
for traffic safety. Epidemiological studies show an in-
creased risk of accidents while driving under the influence
of drugs and/or alcohol (EMCDDA 2008). Data on illicit
substances such as cannabis, amphetamines (including
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MDMA), and other stimulants in traffic seem to point out
that driving home after a party under the influence of so-
called “party drugs” is increasing (Morgan 2000; Ojaniemi
et al. 2009; Walsh et al. 2004). A recent report of the
National Highway and Traffic Safety Association reported
that 10.5% of drivers during nighttime were under the
influence of illicit drugs (Lacey et al. 2009).
Driving is a complex task that requires several cognitive
functions. There is ample evidence that long-term use as well
as acute use of MDMA detrimentally affects cognition.
Multiple reviews have indicated that chronic MDMA use
impairs cognitive performance on tasks measuring working
and episodic memory, attention, frontal-executive functions,
impulsiveness, and psychomotor speed (e.g., Kalechstein et
al. 2007; Morgan 2000; Parrott 2006; Zakzanis et al. 2007).
Acute studies demonstrated attentional and memory deficits
during MDMA intoxication. For example, Kuypers and
Ramaekers (2005, 2007) reported impairments in verbal and
spatial memory performance after a single dose of 75 mg
MDMA. Dumont et al. (2008) also described acute
impairment in memory as well as in attention after a single
dose of 100 mg MDMA. In contrast, psychomotor perfor-
mance improved after a single acute dose of MDMA
(Lamers et al. 2003), showing that MDMA also possesses
stimulating properties.
A number of studies have assessed the effects of MDMA
on driving performance in actual driving studies and
driving simulator studies. Studies that assessed on-the-
road driving performance showed that acute administration
of regular recreational doses of 75 or 100 mg MDMA
improved road-tracking performance (Kuypers et al. 2006;
Ramaekers et al. 2006). However, MDMA also impaired
other aspects of driving such as car-following performance
(Ramaekers et al. 2006). Subjects overreacted to speed
decelerations of a leading car as indicated by a significant
“overshoot” in their adaptive response. Another on-the-road
driving study indicated that the stimulating effects of
MDMA on driving performance were only mild and not
sufficient to counteract the impairing effect of alcohol when
used in combination (Kuypers et al. 2006). The latter
finding was also reported by Brookhuis et al. (2004) who
assessed simulated driving performance of rave party
visitors before and after the party in a quasi-controlled
study. All of the participants used multiple drugs, including
MDMA and alcohol. Drug users clearly had higher
accidents rates and displayed more risk-taking behaviors
early in the morning, when compared to non-drug-using
controls. However, it was difficult to determine whether
these impairments in the drug-using group resulted from
MDMA use, polydrug use, or sleep deprivation.
The present study was designed to assess effects of
MDMA and sleep deprivation on actual driving perfor-
mance, separately and in combination. In addition, the
present study assessed the association between MDMA
concentration in blood and oral fluid. In order to cover a
wide range of concentrations, three doses of MDMA (25,
50, and 100 mg) were included in the design. Driving
performance was measured in the evening after administra-
tion of placebo or MDMA and in the morning after a night
of sleep loss. It was expected that MDMA would produce
stimulant effects in the evening, but impairment in the
morning after a night of sleep loss.
Method
Subjects
Eight males and eight females participated in this study (N=
16). Their mean (SE) age was 22.0 (0.41) years, and their
mean (SE) lifetime MDMA use was 27.0 (8.4) times.
Participants were recruited by advertisements at Maastricht
University and were paid upon completion of the study.
Before enrollment all subjects were screened by means of a
telephone interview to determine whether they qualified for
the study. The inclusion criteria were: experience with
MDMA, i.e., at least one time in the last year; free from
psychotropic medication; good physical health as determined
by a medical examination; absence of any major medical,
endocrine, and neurological condition; normal weight, i.e.,
BMI between 18 and 28; valid driving license; and written
informed consent. The exclusion criteria were history of drug
abuse or addiction; pregnancy or lactation; cardiovascular
abnormalities on electrocardiogram; excessive drinking, i.e.,
more than 20 alcoholic consumptions a week; hypertension,
i.e., systolic blood pressure over 170 mmHg or diastolic
blood pressure over 100 mmHg; and history of or current
psychiatric disorder. If subjects met the inclusion criteria,
they received a medical history and a drug questionnaire to
get a more precise view on their health and drug use. Finally,
participants underwent a medical examination and took part
in a training session.
The study was conducted according to the code of ethics
on human experimentation established by the Declaration
of Helsinki (1964) and amended in Seoul (2008). Approval
for the study was obtained from the Medical Ethics
Committee of the Academic Hospital of Maastricht and
Maastricht University. A permit for obtaining, storing, and
administering MDMA was obtained from the Dutch drug
enforcement administration.
Study design
The study was conducted according to a double-blind,
placebo-controlled, randomized, four-way cross-over design.
Treatments consisted of single doses of placebo and 25, 50,
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and 100 mg MDMA. Treatment orders were balanced over
subjects and treatment periods. Placebo and MDMA were
administered orally in identically appearing formulations.
MDMAwas dissolved in 25-mL bitter orange peel syrup, and
placebo consisted of only the bitter orange peel syrup. The
syrup was mixed with 200 mL juice before it was given to the
participants. The wash-out period between treatments was at
least 1 week.
Procedure
Subjects were asked to refrain from any drugs 1 week before
the medical examination until 2 weeks after study completion.
Subjects were not allowed to drink alcohol and caffeine or
smoke tobacco during a 24-h period prior to testing. Subjects
were always tested for alcohol and drugs in breath and urine
upon arrival (4:30 p.m.) at the laboratory on test days. In case
of a positive result, subjects were sent home and asked to
come back on another day. This happened in the case of one
subject. After repeated violation this subject was excluded and
replaced. At 5:00 p.m. participants received a light, standard
dinner, and at 5:15 p.m.MDMA or placebo was administered.
Driving performance was assessed in the evening and in the
morning after a night of sleep loss and psychomotor
performance in the evening, in the middle of the night, and
in the morning. Karolinska sleepiness scale was administered
throughout the night. The timeline for performance testing,
questionnaires, and blood draws is displayed in Fig. 1. An
additional blood sample was drawn 1 week after each testing
day to monitor renal and liver function. A test day ended at
9:00 a.m. the next morning at which time participants were
driven home.
Actual driving tests
The road-tracking test (O'Hanlon 1984) consists of driving
in a specially instrumented car with a constant speed of
95 km/h and as straight as possible on the right lane of
primary highway during a 1-h test ride. A video camera
mounted on the rear end of the car registers its lateral
position relative to the road delineation. The images are
recorded onto a hard drive in the car with a frequency of
4 Hz and are transformed into a file containing the
measures of the lateral position. An offline editing routine
is applied for removal of all data segments that reveal signal
loss, disturbance, or occurrence of passing maneuvers. The
edited dataset is then used to calculate means and variances
for lateral position. The primary dependent measure of this
test is the standard deviation of lateral position (SDLP; i.e.,
a measure of weaving). Speed and standard deviation of
speed are recorded as secondary control measures. The
highway driving test has been calibrated in a manner
allowing expression of any sedative drug effect in terms of
the blood alcohol concentration (BAC) required to achieve
the equivalent level of driving impairment (Louwerens et
al. 1987). The alcohol calibration curve demonstrates that
drinkers' mean SDLP rises exponentially with BAC.
Results from the alcohol calibration study can be used for
describing drugs' effects on SDLP in terms of respective
BAC equivalencies. The change in SDLP at a BAC of
0.5 mg/ml (i.e., 2.4 cm) has been used as a criterion level to
quantify drug effects. Any drug-induced changes in SDLP
that exceed this criterion value are defined as clinically
relevant impairing drug effect in the present study.
The car-following test (Brookhuis et al. 1994; Ramaekers
et al. 1995) consists of two cars driving in tandem on a
secondary road. The leading vehicle is operated by a study
staff member; the following vehicle is operated by the
subject who is accompanied by a driving instructor. The test
begins with the two vehicles traveling in tandem at speeds of
70 km/h on a secondary highway. Subjects attempt to drive
15–30 m behind the preceding vehicle and to maintain that
headway as it executes a series of deceleration maneuvers.
During the test, the speed of the leading car is automatically
controlled by a modified cruise-control system. At the
beginning it is set to maintain a constant speed of 70 km/h,
and by activating a microprocessor, the investigator can start
sinusoidal speed changes reaching an amplitude of −10%
and returning to the starting level within 50 s. The maneuver
is repeated six to ten times. Speed signals collected during
speed maneuvers enter a power spectral analysis for yielding
phase delay between the vehicle's velocities at the maneuver
cycle frequency (0.02 Hz). Phase delay converted to a
measure of time to speed adaptation (TSA, in seconds) is the
primary measure. Gain and coherence are secondary control
measures. Gain is the amplification factor between both
Fig. 1 Timeline for blood samples, questionnaires, and performance tests relative to drug administration. KSS Karolinska sleepiness scale, Ph
physiological measures, CTT critical tracking task, TQ treatment questionnaire
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speed signals collected from the leading and following
vehicle and indicates the magnitude of overshoot in reaction.
Coherence is a measure to control for correspondence
between both speed signals. Test duration is 25 min.
Critical tracking task
The critical tracking task measures the participant's ability to
control a displayed error signal in a 1st-order compensatory
tracking task. Error appears as horizontal deviation of the
cursor from midpoint on a horizontal, linear scale. Compen-
satory joystick movements null the error by returning the
cursor to the midpoint. The frequency of cursor deviations
and therefore its velocity increase as a stochastic, linear
function of time. The participant is required to make
compensatory movements with a progressively higher
frequency until the participant loses control. The frequency
at which control loss occurs is 1c (the critical frequency).
The reciprocal of this frequency is theoretically the percep-
tual/motor delay lag for humans operating in a closed-loop
system. The participant performs this test in five trials, and
the mean 1c is recorded as the final score (Jex et al. 1966).
Karolinska sleepiness scale
The Karolinska sleepiness scale is a subjective rating scale
with scores that range from 1, “extremely alert,” to 9, “very
sleepy, great effort to keep alert, fighting sleep” (Åkerstedt
and Gillberg 1990). Participants are instructed to report
their experienced sleepiness during the preceding 10 min.
Reyner and Horne (1998) modified the original scale by
adding verbal descriptions to intermediate steps, which do
not have any descriptions in the original version.
Pharmacokinetic assessment
Blood samples (10 mL) and oral fluid (1–2 mL) samples
were collected throughout a testing day/night, i.e., at 1.5
and 11 h post drug. The blood sample was centrifuged
immediately, and the resulting serum was frozen at −20°C
until analyses for pharmacokinetic assessments. MDMA
concentrations and its main metabolite 3,4-methylenediox-
yamphetamine (MDA) were determined in the corresponding
serum samples using solid phase extraction and gas chroma-
tography with mass spectrometric (GC-MS) detection with a
limit of quantification of 16.8 ng/mL. Oral fluid was collected
with the Orasure Intercept® device for a quantitative analysis
of MDMA concentrations by GC-MS.
Statistical analyses
All statistical analyses were conducted by means of SPSS
16.0 for Mac. Statistical analyses consisted of two steps: (1)
assessment for overall treatment effects by means of
superiority testing, (2) equivalence or non-inferiority testing
of drug effects based on difference scores from placebo
(within group) relative to the pre-established alcohol
criterion, and (3) determination of concentration-effect
relations. Steps 2 and 3 were only conducted in case of
treatment effects and only for the primary measures of
driving performance.
During step 1 all data entered the general linear model
repeated measures ANOVA procedures with MDMA (four
levels) and hours of sleep loss (two levels for driving tests,
three levels for cognitive test, and eight levels for subjective
test) as main within-subject factors. If the sphericity assump-
tion was violated or not applicable, the Greenhouse–Geisser
correction was used. In the case of an overall effect of
MDMA, separate drug-placebo contrast analyses were con-
ducted for each MDMA dose.
Step 2 assessed whether a pre-established alcohol
criterion falls within the 95% confidence interval (CI) of
the drug effect. If yes, than the drug effect was considered
to be equivalent or bigger than a BAC of 0.5 mg/mL and
thus relevant for traffic safety. If the 95% CI was lower than
the alcohol criterion value, than a drug effect was
considered of no clinical relevance.
In step 3, concentration-effect relations were deter-
mined according to the following procedure. Data
collected during different doses of a drug were converted
to change scores from placebo for analyses of the
association between drug concentration and performance.
A linear regression analysis was conducted to establish
linear relationships between changes (from placebo) in
task performance during drug treatment and log-
transformed drug concentrations in serum. The total
number of data points included in these equations was
defined by the number of subjects × maximal number
test repetitions × the number of drug doses. Individual
drug concentrations in serum prior to performance
assessments in each of the drug dose conditions were
divided over three mutually exclusive categories covering
the full range of drug concentrations. The concentration
ranges in serum were 0–50, 50–100, and >100 ng/mL
during evening sessions and 0–25, 25–50, and >50 ng/mL
during morning sessions. The concentration ranges in oral
fluid were 0–250, 250–1,000, and >1,000 ng/mL during
evening sessions and 0–100, 100–500, and >500 ng/mL
during morning sessions. Corresponding change scores of
task performance were then classified either as showing
“impairment” or “no impairment” for all individual cases
within each of these categories. Impairment was defined as a
positive change score from placebo. Binomial tests were
applied to measure whether the proportion of observations
showing impairment or no impairment significantly differed
from the hypothesized proportion. It was hypothesized that in
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the case of no effect of a drug on task performance, the
proportion of observations showing impairment or no
impairment would be equal, i.e., 50%.
Results
Dropouts and missing data
Two participants dropped out. One was positive for Δ9-
tetrahydrocannabinol in urine. The other indicated that the
sleep loss interfered too much with his daily life. Both
dropouts were replaced. Data were missing in the car-
following test on some occasions. These missing values
were replaced by the overall group mean for the respective
treatments.
Driving tests prematurely terminated
Table 1 shows the highway driving tests that were
prematurely terminated, the drug condition in which the
test was terminated, the reasons for termination, the initiator
of termination, the measured SDLP, and distance traveled
before termination.
The car-following test was prematurely terminated in
two cases (1.6%), once in the placebo condition and once
in the 25-mg MDMA condition. Both tests were
terminated in the morning and by the instructor because
of sleepiness of the subject. In case of a premature stop,
available data till time of test termination were used for
statistical analysis.
Driving tests
Mean (SE) performances on the primary (SDLP and TSA)
and secondary measures of the highway driving and car-
following test are shown in Table 2. MDMA did not affect
any of the driving measures. Sleep loss significantly affected
SDLP (F1,15=40.833, p<0.001) and SD speed (F1,15=
29.905, p<0.001). SDLP and SD speed were markedly
higher in the morning as compared to the evening. The
interaction between MDMA and sleep loss only reached
significance SD speed (F3,45=3.607, p=0.020). SD speed
was higher in the morning as compared to the evening,
Table 1 Drug conditions of and
reasons for dropouts in highway
driving test, mean SDLP and







Reason/terminated by Mean SDLP (cm) Distance
traveled (km)
3 25 Morning Sleepiness/instructor 26.59 92
3 100 Morning Sleepiness/subject 22.50 64
4 0 Morning Sleepiness/instructor 23.88 99
4 50 Morning Sleepiness/instructor 23.30 29
6 50 Morning Sleepiness/subject 18.69 31
6 100 Morning Sleepiness/instructor 22.25 88
7 0 Morning Sleepiness/subject 24.94 66
7 100 Evening Anxiousness/subject 20.02 61
7 100 Morning Sleepiness/instructor 33.72 11
9 0 Morning Sleepiness/instructor 29.53 25
9 50 Morning Sleepiness/instructor 28.95 32
9 100 Morning Sleepiness/instructor 23.49 43
10 0 Morning Sleepiness/subject 22.57 48
10 25 Morning Sleepiness/subject 21.23 31
10 50 Morning Sleepiness/instructor 17.25 32
10 100 Morning Sleepiness/instructor 31.24 13
11 25 Morning Sleepiness/instructor 21.83 59
11 50 Evening Sleepiness/instructor 28.62 63
11 50 Morning Sleepiness/instructor 28.85 54
15 0 Morning Sleepiness/instructor 29.43 14
15 25 Morning Sleepiness/instructor 26.60 31
15 50 Evening Sleepiness/instructor 23.30 61
15 50 Morning Sleepiness/instructor 25.76 29
15 100 Morning Sleepiness/instructor 22.61 9
16 0 Morning Sleepiness/instructor 25.89 47
16 25 Morning Sleepiness/subject 19.74 65
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particularly after treatment with MDMA 100 mg (p=0.017).
In general, variations in mean SD speed were very small and
ranged between 1 and 2.5 km/h.
Equivalence testing demonstrated that increments in SDLP
in the morning in all treatment conditions were equivalent to a
BAC of 0.8 mg/mL when compared to placebo performance
in the evening. The upper limits of the 95% CI of changes
induced by sleep loss clearly exceeded the pre-established
inferiority margin of 2.4 cm. Mean change SDLP and 95% CI
in every treatment condition are shown in Fig. 2.
Regression analysis of MDMA levels in serum and
SDLP change scores showed a general lack of correlation
between the measures. Scatterplots showing the linear
relationship between MDMA levels in serum and oral fluid
and changes in SDLP are shown in Fig. 3.
Binomial tests showed a significant increase in the
proportion of observations showing impairment in the
highway driving test when conducted in the morning for
serum MDMA concentrations between 0–25 and >50 ng/mL
(p<0.05). In oral fluid all concentration ranges were
associated with impairment (p<0.05). Impairments were
only apparent when compared to placebo SDLP during
evening sessions. Distributions of observations showing
“impairment” and “no impairment” in the highway driving
test as a function of MDMA in serum and oral fluid are
shown in Fig. 4.
Fig. 2 Mean (95% CI) SDLP difference from placebo after single
doses of MDMA during the road-tracking test in the evening and in the
morning after a night of sleep loss. (* = non-inferiority not shown; the
upper bound of the 95% CI is above the non-inferiority margin of 2.4 cm)
Table 2 Mean (SE) of the driving and psychomotor tests and subjective measure for the treatment conditions and measuring times












SDLP (cm) 1 18.2 (0.7) 18.4 (0.8) 18.1 (1.0) 18.0 (0.6) <0.001 NS NS
2 22.8 (0.8) 22.9 (0.6) 21.7 (0.9) 22.4 (1.1)
SD speed (km/h) 1 1.70 (0.13) 1.74 (0.14) 1.88 (0.17) 2.14 (0.14) <0.001 NS 0.020
2 2.68 (0.23) 2.62 (0.19) 2.66 (0.18) 2.46 (0.19)
Car following
TSA (s) 1 2.8 (0.2) 3.0 (0.2) 3.0 (0.3) 2.7 (0.2) NS NS NS
2 3.3 (0.4) 3.3 (0.4) 3.2 (0.3) 3.1 (0.5
Coherence 1 0.9 (0.01) 0.9 (0.01) 0.9 (0.01) 0.9 (0.01) NS NS NS
2 0.9 (0.01) 0.9 (0.01) 0.9 (0.01) 0.9 (0.01)
Gain 1 1.1 (0.04) 1.2 (0.03) 1.0 (0.03) 1.1 (0.03) NS NS NS
2 1.1 (0.03) 1.1 (0.03) 1.1 (0.04) 1.2 (0.06)
Critical tracking task
λc (rad/s) 1 3.77 (0.13) 3.83 (0.16) 3.70 (0.15) 3.78 (0.19) <0.001 NS NS
2 3.63 (0.16) 3.56 (0.18) 3.73 (0.16) 3.77 (0.16)
3 3.09 (0.19) 2.87 (0.22) 3.09 (0.19) 3.36 (0.17)
Karolinska sleepiness scale
Score 1 2.94 (0.21) 2.94 (0.27) 2.88 (0.36) 2.94 (0.25) <0.001 NS NS
2 3.13 (0.32) 2.69 (0.25) 2.19 (0.21) 1.81 (0.25)
3 3.62 (0.32) 3.69 (0.29) 3.62 (0.38) 3.62 (0.41)
4 4.44 (0.35) 4.62 (0.38) 4.25 (0.41) 5.13 (0.40)
5 5.31 (0.40) 5.81 (0.45) 5.44 (0.35) 6.12 (0.42)
6 5.88 (0.39) 6.50 (0.45) 6.19 (0.38) 5.81 (0.44)
7 7.38 (0.30) 7.69 (0.37) 7.50 (0.32) 7.56 (0.33)
8 7.38 (0.44) 7.88 (0.36) 7.62 (0.40) 7.62 (0.42)
Significance is indicated by p value
SDLP standard deviation of lateral position, NS not significant, TSA time to speed adaptation
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Critical tracking task
Mean 1c (critical frequency) of the critical tracking task was
significantly affected by sleep deprivation (F2,30=34.516,
p<0.001). Mean critical frequency generally decreased during
the night, indicating diminished psychomotor control. Critical
tracking was not affected by MDMA or MDMA × sleep loss.
Karolinska sleepiness scale
The Karolinska sleepiness scale showed a significant effect of
sleep loss (F2.972,44.576=108.717, p<0.001). The Karolinska
sleepiness scale also demonstrated a significant dose-related
MDMA effect at Tmax (F3,45=6.006, p=0.002). Contrasts
indicated that the 100-mg as well as 50-mg MDMA
Fig. 3 Correlations between
change SDLP and log-converted
MDMA concentrations in serum
(left panels, a–b) and saliva (right
panels, c–d) during driving tests
in the evening (upper panels, a
and c) and in the morning (lower
panels, b and d)
Fig. 4 Percentage of observa-
tions showing MDMA-induced
impairment or MDMA-induced
improvement of SDLP in the
road-tracking task, as a function
of MDMA concentrations in
serum (left panels, a–b) and
saliva (right panels, c–d) during
driving tests in the evening
(upper panels, a and c) and in
the morning after a night of
sleep loss (lower panels, b and
d). * p<0.05
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conditions differed significantly from placebo (p=0.009 and
p=0.023, respectively).
Pharmacokinetic assessment
Pharmacokinetic analysis in serum revealed mean (SE)
MDMA concentrations of 25.8 (3.3), 63.9 (6.4), and 157.2
(9.5) ng/mL at 1.5 h after administration of a 25-, 50-, and
100-mg dose, respectively. At 11 h post-drug, mean MDMA
concentrations were 14.2 (2.7), 34.0 (3.9), and 84.3 (6.7) ng/
mL, respectively. MDA concentrations were 3.5 (0.1), 3.9
(0.4), and 5.8 (0.2) ng/mL 1.5 h post drug and 2.9 (0.5), 5.8
(0.2), and 9.7 (0.6) ng/mL after 11 h for 25, 50, and 100 mg
MDMA, respectively.
Mean (SE) MDMA concentrations in oral fluid were
208.2 (72.4), 833.0 (270.9), and 3417.8 (694.2) ng/g, and
MDA concentrations were 3.2 (1.5), 13.9 (4.2), and 56.4
(13.5) ng/g for 25, 50, and 100 mg MDMA, respectively, at
1.5 h post drug. The concentrations at 11 h after drug intake
were respectively 57.0 (16.3), 292.6 (79.0), and 925.3
(224.7) ng/g for MDMA and 3.6 (1.4), 18.9 (4.4), and 56.8
(12.8) ng/g for MDA.
Discussion
The present study demonstrated that sleep deprivation
produced severe impairment in actual driving performance
as expressed by a significant rise in SDLP and a large
number of prematurely terminated driving tests during early
morning sessions. In general, MDMA did not affect actual
driving performance and did not interact with the effects of
sleep deprivation.
On average, SDLP increased with 4.2 cm in the morning
after sleep deprivation, relative to SDLP before sleep
deprivation. This increment is about 1.5–2 times greater
than found in two recent driving under the influence of
alcohol studies with blood alcohol concentrations between
0.29 and 0.5 mg/mL (Kuypers et al. 2006; Ramaekers et al.
2000). From a previous alcohol study that was conducted in
order to calibrate SDLP for the dose-related effects of
alcohol (Louwerens et al. 1987), it can be concluded that a
mean increase in SDLP of 4.2 cm is equivalent to a blood
alcohol concentration of approximately 0.8 mg/mL. Equiv-
alence testing even demonstrated that the upper limit of the
95% CI associated with the mean change in SDLP after
sleep deprivation widely exceeded the criterion level of
1.0 mg/mL BAC. Together, this indicates that sleep
deprivation caused severe driving impairment comparable
to driving under the influence of high to very high BAC.
These findings were corroborated by results from the
critical tracking task. Critical tracking performance signif-
icantly decreased over the night, as a function of hours of
sleep loss. Similar findings have previously been reported
by Dawson and Reid (1997). They measured tracking
performance as a function of hours of sleep loss and BAC
intoxication. According to their model, tracking perfor-
mance of subjects after 17–24 h of wakefulness is
equivalent to that observed at BAC between 0.5 and
1.0 mg/mL. This again indicates that a night of sleep
deprivation causes serious impairment of driving skills. In
terms of BAC equivalents, these impairments exceeded
those observed at legal BAC limits of 0.5 and 0.8 mg/mL
that are currently in place for driving under influence of
alcohol in most of Europe and the USA.
The car-following test was the only driving measure that
did not show an effect of sleep loss. This diverging effect
between the two driving tests, i.e., road tracking and car
following, could be explained by a study of Harrison and
Horne (2000). They conducted a study in which they
showed that dull and monotonous tasks are more sensitive
to sleep deprivation than more complex, rule-based tasks,
because the latter ones generate more interest and effort to
compensate for the effects of sleep deprivation. The
highway driving test is monotone, and subjects reported
that it was more boring than the car-following test, which is
more complex. This is corroborated by the fact that 20% of
road-tracking and 2% of car-following tests were prema-
turely terminated, of which the majority were in the
morning, i.e., after sleep deprivation. Therefore, this
divergence between the two driving tests are in line with
the results of Harrison and Horne (2000), in that the more
monotone road-tracking test is more sensitive to sleep
deprivation than the car-following test.
In general, MDMA did not produce any significant
effects on driving parameters independent of dose or
concentration. Stimulating effects of MDMA on actual
driving parameters or psychomotor measures that have been
demonstrated before (e.g., Dumont et al. 2008; Kuypers et
al. 2006, 2007; Lamers et al. 2003; Ramaekers et al. 2006)
could not be clearly replicated in the present study. This
discrepancy could be due to the fact that the present study
also included lower doses of MDMA, i.e., 25 and 50 mg,
that may be less likely to produce stimulatory effects than
MDMA between 75 and 125 mg that have been tested in
the studies mentioned above. However, even in the present
study, some measures tended to show stimulatory effects of
MDMA. For example, SD speed was significantly affected
by an interaction between sleep loss and MDMA. Overall,
SD speed increased after a night of sleep loss, but this
increase was somewhat less after 100 mg MDMA. Also,
binomial tests of SDLP change scores in the evening
demonstrated that the majority of observations indicated a
reduction in SDLP, particularly at lower MDMA concen-
trations. However, this effect failed to reach statistical
significance.
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It is also apparent from the present study that the
stimulant effects of MDMA, if any, could not compensate
for the impairing effect of sleep loss on driving perfor-
mance. None of the primary driving measures demonstrated
any significant MDMA x sleep loss interaction. The effects
of sleep deprivation on driving were highly prominent
during MDMA treatments and did not change as a function
of dose and concentration. These findings are in line with
those in a previous study that assessed the stimulant effects
of MDMA on SDLP during alcohol intoxication (Kuypers
et al. 2006). That study demonstrated that stimulatory
effects of MDMA did not compensate for driving impair-
ment caused by alcohol. Together, these data indicate that
the effects of MDMA on psychomotor functions are neutral
or mildly stimulating, but that these effects are not
sufficient to overcome impairments caused by other factors
such as sleep deprivation or alcohol intoxication.
The latter notion is of crucial importance when evaluat-
ing driving under the influence (DUI) offenders involving
the use of MDMA. Subjects in the present study were
significantly impaired during MDMA treatments when
deprived of sleep for one night. However, the prime factor
causing these impairments was sleep deprivation rather than
the use of MDMA itself. When applied in courts, one could
rightfully pose the argument that such drivers should not be
prosecuted for DUI since MDMA did not contribute to the
impairments of the driver. There are a number of counter
arguments that should be taken into consideration when
evaluating MDMA cases in traffic. First, it has been
demonstrated in previous studies that single doses of
MDMA increase subjective feelings of arousal and mood
(Bosker et al. 2010; Kuypers et al. 2008) and the current
study showed a decrease in sleepiness from baseline at Tmax
in the MDMA conditions. Such feelings may affect the
subjective judgment of MDMA users on whether or not it is
safe to drive home after spending a night at a rave party.
During MDMA intoxication, they may not be able to
subjectively experience the debilitating effects of sleep loss
to the same degree as drug-free drivers, because they feel
energetic. As a consequence, they may decide to drive
because they feel alert, thereby neglecting the impairing
effects of other impairing factors such as sleep deprivation
or even alcohol use. Secondly, several studies have also
demonstrated that cognitive functions such as working
memory, spatial memory, and timing of moving objects
(Kuypers and Ramaekers 2005; Lamers et al. 2003;
Ramaekers et al. 2009) are impaired during MDMA
intoxication. Such cognitive impairments may also affect
a person's ability to reflect on his/her fitness to drive as well
driving ability in general.
It is concluded from this study that drivers who are
under the influence of MDMA and are sleep deprived are
unfit to drive. The impairing effects of sleep deprivation
during MDMA intoxication occurred independent of
MDMA dose and concentration.
Acknowledgments This work was conducted as part of the DRUID
research consortium funded by EU grant TREN-05-FP6TR-
S07.61320-518404-DRUID.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Åkerstedt T, Gillberg M (1990) Subjective and objective sleepiness in
the active individual. Int J Neurosci 52:29–37
BoskerWM,Kuypers KPC, Conen S, Ramaekers JG (2010) Dose-related
effects of MDMA on psychomotor function and mood before,
during, and after a night of sleep loss. Psychopharmacology (Berl)
209:69–76
Brookhuis KA, de Waard D, Mulder B (1994) Measuring driving
performance by car-following in traffic. Ergonomics 37:427–434
Brookhuis KA, de Waard D, Samyn N (2004) Effects of MDMA
(ecstasy), and multiple drugs use on (simulated) driving perfor-
mance and traffic safety. Psychopharmacology (Berl) 173:440–445
Dawson D, Reid K (1997) Fatigue, alcohol and performance
impairment. Nature 388:235
Dumont GJ, Wezenberg E, Valkenberg MM, de Jong CA, Buitelaar
JK, van Gerven JM, Verkes RJ (2008) Acute neuropsychological
effects of MDMA and ethanol (co-)administration in healthy
volunteers. Psychopharmacology (Berl) 197:465–474
EMCDDA (2008) EMCDDA insights series no. 8: drug use, impaired
driving and traffic accidents. Office for Official Publications of
the European Communities, Luxembourg
Harrison Y, Horne JA (2000) The impact of sleep deprivation on
decision making: a review. J Exp Psychol Appl 6:236–249
Jex HR, McDonnell JD, Phatak AV (1966) A “critical” tracking task
for man-machine research related to the operator’s effective delay
time. I. Theory and experiments with a first-order divergent
controlled element. NASA CR-616. NASA Contract Rep NASA
CR: 1–105
Kalechstein AD, De La Garza R 2nd, Mahoney JJ 3rd, Fantegrossi
WE, Newton TF (2007) MDMA use and neurocognition: a meta-
analytic review. Psychopharmacology 189:531–537
Kuypers KPC, Ramaekers JG (2005) Transient memory impairment after
acute dose of 75 mg 3.4-methylene-dioxymethamphetamine. J
Psychopharmacol 19:633–639
Kuypers KPC, Ramaekers JG (2007) Acute dose of MDMA (75 mg)
impairs spatial memory for location but leaves contextual processing
of visuospatial information unaffected. Psychopharmacology (Berl)
189:557–563
Kuypers KPC, Samyn N, Ramaekers JG (2006) MDMA and alcohol
effects, combined and alone, on objective and subjective
measures of actual driving performance and psychomotor
function. Psychopharmacology (Berl) 187:467–475
Kuypers KPC, Wingen M, Samyn N, Limbert N, Ramaekers JG
(2007) Acute effects of nocturnal doses of MDMA on measures
of impulsivity and psychomotor performance throughout the
night. Psychopharmacology (Berl) 192:111–119
Kuypers KPC, Wingen M, Ramaekers JG (2008) Memory and mood
during the night and in the morning after repeated evening doses
of MDMA. J Psychopharmacol 22:895–903
Psychopharmacology (2012) 222:367–376 375
Lacey JH, Kelley-Baker T, Furr-Holden D, Voas RB, Romano E,
Ramirez A, Brainard K, Moore C, Torres P, Berning A (2009)
2007 national roadside survey of alcohol and drug use by
drivers: drug results (DOT HS 811 249). US Department of
Transportation, National Highway Traffic Safety Administration,
Washington
Lamers CT, Ramaekers JG, Muntjewerff ND, Sikkema KL, Samyn N,
Read NL, Brookhuis KA, Riedel WJ (2003) Dissociable effects
of a single dose of ecstasy (MDMA) on psychomotor skills and
attentional performance. J Psychopharmacol 17:379–387
Louwerens J, Gloerich A, de Vries G, Brookhuis K, O’Hanlon J
(1987) The relationship between drivers’ blood alcohol concen-
tration (BAC) and actual driving performance during high speed
travel. Alcohol Drugs Traffic Saf 86:183–186
Morgan MJ (2000) Ecstasy (MDMA): a review of its possible persistent
psychological effects. Psychopharmacology (Berl) 152:230–248
O’Hanlon JF (1984) Driving performance under the influence of
drugs: rationale for, and application of, a new test. Br J Clin
Pharmacol 18(Suppl 1):121S–129S
Ojaniemi KK, Lintonen TP, Impinen AO, Lillsunde PM, Ostamo AI
(2009) Trends in driving under the influence of drugs: a register-
based study of DUID suspects during 1977–2007. Accid Anal
Prev 41:191–196
Parrott AC (2006) MDMA in humans: factors which affect the neuro-
psychobiological profiles of recreational ecstasy users, the integra-
tive role of bioenergetic stress. J Psychopharmacol 20:147–163
Ramaekers JG, Muntjewerff ND, O’Hanlon JF (1995) A comparative
study of acute and subchronic effects of dothiepin, fluoxetine and
placebo on psychomotor and actual driving performance. Br J
Clin Pharmacol 39:397–404
Ramaekers JG, Robbe HW, O’Hanlon JF (2000) Marijuana, alcohol and
actual driving performance. Hum Psychopharmacol 15:551–558
Ramaekers JG, Kuypers KPC, Samyn N (2006) Stimulant effects of
3,4-methylenedioxymethamphetamine (MDMA) 75 mg and
methylphenidate 20 mg on actual driving during intoxication
and withdrawal. Addiction 101:1614–1621
Ramaekers JG, Kuypers KP,WingenM, HeineckeA, Formisano E (2009)
Involvement of inferior parietal lobules in prospective memory
impairment during acute MDMA (ecstasy) intoxication: an event-
related fMRI study. Neuropsychopharmacology 34:1641–1648
Reyner LA, Horne JA (1998) Falling asleep whilst driving: are drivers
aware of prior sleepiness? Int J Legal Med 111:120–123
SAMHSA (2009) Results from the 2008 National Survey on Drug
Use and Health: national findings. Office of Applied Studies,
NSDUH series H-36, HHS publication no. SMA 09–4434).
Office of Applied Studies, NSDUH series H-36, HHS publication
no. SMA 09–4434), Rockville, MD
Walsh JM, de Gier JJ, Christopherson AS, Verstraete AG (2004)
Drugs and driving. Traffic Inj Prev 5:241–253
Zakzanis KK, Campbell Z, Jovanovski D (2007) The neuropsychology of
ecstasy (MDMA) use: a quantitative review. Hum Psychopharmacol
22:427–435
376 Psychopharmacology (2012) 222:367–376
